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ABSTRACT 
Research objective: to assess efficiency of application of bio preparations in the 
correction of intestinal dysbacteriosis taking into account the results of “Load” test in vitro in 
children with chronic hepatitis B together with giardiasis. 
Material and methods. We examined one hundred and fifty children with chronic 
hepatitis B (CHB) with concomitant giardiasis in the age from 3 to 18 years old. The diagnosis 
was based on data from history, results of clinical tests, biochemical and instrumental tests. 
Laboratory diagnostics of giardiasis was performed using the following methods: immune 
fluorescent method (G. Lamblia antigen in feces), polymerase chain reaction (G. Lamblia DNA 
in blood and feces), and triple microscopic test for precipitation components of feces. For the 
definition of lymphocyte sensitivity to bio preparations to choose the agent we applied loading 
test in vitro. For the correction of dysbacteriosis using the basic therapy we used very sensitive 
polycomponent probiotics in capsules such as “Bifilax-immuno”, “Lacto-G”, and “Narimax-
plus”.Lamblia eradication was performed using Macmirror (Nifuratel) 15mg/kg two times a day 
for 10 days. Assessment of the efficiency of the prescribed therapy was done according to the 
clinical, biochemical, and bacteriological data. 
Results. We determined a direct proportional decrease of lymphocyte ability for E-rosette 
formation dependent on the expression of intestinal dysbacteriosis. The most sensitive 
biopreparation in in vitro test was Bifilax-immuno (62.7%), which differed by its quantitative 
and qualitative composition compared to Lacto-G (48.0%) and Narimax-plus (38.7%), р<0.05. 
Prescription of anti-giardiasis therapy with individually chosen very sensitive biopreparation for 
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the correction of intestinal dysbacteriosis in children with CHB provided achievement of 
stabilization (60.0%) and regression of pathological process in liver, prevention of unfavorable 
outcomes such as hepatic cirrhosis and hepatocellular carcinoma. 
Conclusion. Differential approach to the choice of probiotic for the correction of 
intestinal dysbacteriosis provides the increase of the efficiency of therapy in children with CHB 
with concomitant giardiasis by 40.1%. Development of clinical, biochemical, and 
microbiological remission was achieved using Bifilax-immuno in 76.5% cases, Lacto-G in 
64.4%, and Narimax-plus in 62.0% of the cases respectively (p < 0.01). In relation to that, 
children with CHB and concomitant giardiasis together with the test for intestinal dysbacteriosis 
have to undergo loading test in vitro for the prescription of efficient and targeted correction 
taking into account individual sensitivity of an organism to biopreparations. 
 
Key words: chronic hepatitis B, giardiasis, intestinal dysbacteriosis, therapy, 
biopreparations, children. 
 
INTRODUCTION 
 
In spite of vaccination against hepatitis B and achievements in the field of chronic viral 
hepatitis diagnostics and therapy in children, that problem continues to be topical one for the 
world and local health care systems. According to the WHO data the are more than 500 million 
people in the world infected by Hepatitis-B virus, which is among the ten most prevalent death 
causes among the population, every year taking the lives of about 1.5 million people and 
possesses strong oncogenic potential [1]. One of the pathogenic sections in the development of 
pathological process in the liver of children with chronic hepatitis B is dysbiotic alterations in 
intestine, causing initiation of a cascade of pathological reactions promoting progression of the 
pathology [2,3]. Earlier in our studies we revealed high prevalence (99.7%) of intestinal 
dysbacteriosis (ID) among the children with CHB independently of presence or absence of 
giardiasis [4]. In the conditions of chronic viral persistence intestinal dysbacteriosis promotes 
development of disorders in secretory, motor, and barrier functions of intestine, and makes all 
ways of lamblia introduction real [5]. Initsturn, in the conditions of aggressive medium in cases 
of ID lamblia secrete more toxins promoting generalization of viral infection with outgoing 
complications such as polysystemic organic failure [6]. In the result it leads to the suppression of 
macro organism resistance, and in the conditions of combined viral-parasite infection it promotes 
the development of two parallel mutually-deteriorating processes. In the modern time due to the 
enormous variety of probiotics available on pharmaceutical market, which are blindly used, there 
is a pending problem of the choice of optimal bio preparation. According to the results of our 
studies, efficiency of existing correction methods used for intestinal micro ecology is balance is 
equal to 62.2% only [7]. Taking into account that fact, and recently registered characteristic 
development of microbiot a resistance to biopreparations [8, 9], a question of the search for new 
diagnostic methods allowing short-term, targeted, and maximally effective choice a bio 
preparation for ID correction in children with CHB appeared. The objective of the study was to 
assess the efficiency of bio preparation prescription for the correction of ID taking into account 
in vitro “load” test results in children with chronic hepatitis B with background giardiasis [10]. 
 
MATERIALS AND METHODS 
  
We observed one hundred and fifty children with CHB with concomitant giardiasis in the 
age from 3 to 18 years old. CHB diagnosis was based on the data from case history, clinical, 
biochemical, and instrumental tests. Verification ofНВV-infection was done with the help of EIA 
and PCR (НВsAg, НВsAb, НВеAg, НВеAb, HBcorAb, НВV-DNA). Laboratory diagnostics of 
giardiasis was performed using the following methods: immune fluorescent method (G. Lamblia 
antigen in feces), polymerase chain reaction (G. Lamblia DNA in blood and feces), and triple 
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microscopic test for precipitation components of feces.In compliance with the guidelines 
proposed by I.B. Yershova (2002) [11], all patients had double test of intestinal micro flora for 
dysbacteriosis according to Epstain-Litvak’s and F.L. Vishanskay’s method (1977) using V.M. 
Granitov’s classification(2002).  
For the definition of lymphocytes sensitivity to bio preparations we used “load” test in 
vitro for the choice of bio preparation (Patent UZIAP 04570, 2012) [12]. In this method 
performance of the assessment of T-lymphocytes functional activity in E-rosette formation 
reaction in vitro incubation with probiotic is stipulated, providing the choice of effective bio 
preparation in each certain case taking into account individual sensitivity. For the control we 
determined amount of E-rosette forming cells (E-RFC) in blood plasma of these patients without 
stimulation. We calculated the number of stimulated cells (NSC) based on the difference of E-
RFC number between the study and the control groups. In compliance with the method we 
worked out 3 types of reactions: 
1-sttypereaction– hyperergic, increase of the number of E-rosette forming lymphocytes of 
the experimental sample above 5% in case of probiotic addition compared to the control sample; 
i.e. those not losing the ability to form E-rosettes under the influence of the agent. That reaction 
type indicates high sensitivity of an organism to that agent. 
2-ndtypereaction–hypoergic, decrease of E-rosette forming lymphocytes in the 
experimental sample below 5% in case of the agent addition compared to the control sample; i.e. 
those losing ability to form E-rosettes under the influence of the preparation. Hypoergic type 
indicates low sensitivity of an organism to that agent.  
3-rdtypereaction – withoutalterations, i.e. no difference between the experimental and 
control samples, indicating there is no sensitivity of an organism to that agents. 
For the correction of dysbacteriosis we applied polycomponent probiotics in capsules such 
as Bifilax-immuno containing 10х109 CFUL.paracaseiCRL-431 and B.animal is BB-12 
(Pharmaxx International, Denmark), Lacto-G containing 5х109CFUL.acidophilus, B.longum, 
B.bifidum, B.infantisand fructose oligosaccharides (GMP, Georgia) and Narimax-plus 
containing 2.2х108CFUL.acidophilus, L.rhamnosus, L.bulgaricus, L.salivarius, 
B.bifidumandSt.thermophilus(Vitamax Ltd., Yerevan). 
ID bio correction was done with background basic therapy in compliance with the results 
of “load” test using very sensitive bio preparation. Comparison group consisted of 60 children 
with CHB and giardiasis, who received dry bacterial preparations such as bifida and 
lactobacteria in common doses for a month together with background basic therapy. Lambliae 
radication was performed by means of Macmirror (nifuratel), in the dose 15mg/kg two times a 
day for 10 days, which is more effective and safe for children with CHB compared to other anti-
giardiasis agents [13,14]. Assessment of the efficiency of the applied therapy was performed 
according to clinical, biochemical, and bacteriological data. 
Statistical processing was done by means of variation statistics method using Student’s t-
criterion with special Excel-2017 software. Differences were considered to be reliable in case of 
p<0.05. 
RESULTS AND DISCUSSION 
Distribution of sick children according to CHB activity showed that, with background 
giardias is the disease progressed. So, prevailing majority (80.0%) of the patients had moderate 
(71.7%)and expressed (28.3%) activity of the pathology, while the rest (20.0%) of children were 
diagnosed with minimal activity of the pathology. The term of CHB was equal to 4.1±0.2 years. 
Bacteriological test of excrements for micro biocoenosis in all 75 patients displayed intestinal 
dysbacteriosis of the II (50), III (50), and IV (50) stages. 
Analysis of the results of “load” test in vitro showed (Table 1) that, in case of IDII stage in 
68.0% of the children there was notably high sensitivity f an organism to Bifilax-immuno, where 
the amount ofE-RFCwas reliably higher up to 58.2±1.2%, (р<0.001 to the control). NSC was 
equal to9.1±0.94% (р<0.01). In case of stimulation with Lacto-G hyper ergic type reaction was 
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determined in the blood of 60.0% of the children, number of E-RFC was increased up to 
54.1±0.7% (р<0.01 to the control). NSC under the influence of the preparation was only 
5.0±0.7%. We revealed no reliable differences in the numbers of E-RFC with Narimax-plus. It 
was notable that, under the influence of Bifilax-immuno NSC was reliably higher then under the 
influence of Lacto-G (р<0.05), indicating stronger immune tropic capability of Bifilax-immuno 
[15].  
In case of IDIII stage results of the loading test in vitro showed that under the influence of 
Bifilax-immuno hyper ergic type reaction was revealed in 60.0% of the children with CHB, 
when the number ofE-RFC was increased up to 54.3±1.2%, (р<0.05 to the control). NSC under 
the influence of the preparation was 8.0±0.95%. Lacto-G preparation did not sufficiently effect 
the increase of E-RFC number (49.0±1.4% р>0.05), while NSC was only 2.7±0.3%, indicating 
low immune tropic capability of the preparation in children with ID III stage. Narimax-plus also 
did not sufficiently stimulated the ability of lymphocytes for E-rosette formation. The number of 
E-RFC was 47.2±1.3% in 40.0% of the children (р>0.05). NSC was only 0.9±0.4%, indicating 
inefficiency of the preparation [16].  
Analysis of the mean values of the loading test results in children with CHB and ID IV 
stage showed that hyperergic type reaction to Bifilax-immuno was revealed in 54.0% of the 
cases when the number of E-RFC was increased up to 48.0±1.1% (р<0.05). NSC under the 
influence of the preparation was equal to 8.2±0.83%.  Preparations Lacto-G and Narimax-plus 
did not sufficiently effect the formation of E-RFC and did not reveal statistical difference 
between the values of the control sample, (р>0.05). NSC was equal to 2.3±0.12% and 
1.4±0.11%, respectively.  
 
Table 1. Results of the loading test in vitro in children with CHB with concomitant 
giardiasis dependently on the ID stage (E-RFCМ±m, %). 
 
Preparations  ID II stage(n=50) ID III stage (n=50) ID IV stage(n=50) 
Experiment  Control  Experiment  Control  Experiment  Control  
Hyper ergic type reaction 
Bifilax-immuno 
_%_ 
E-RFC,% 
 
68.0±9.3 
58.2±1.2* 
 
 
 
 
 
49.1±1.4 
 
64.0±9.6 
54.3±1.2* 
 
 
 
 
 
46.3±1.2 
 
56.0±9.9 
48.0±1.1* 
 
 
 
 
 
39.8±1.1 
NSC,% 9.1±0.9а 8.0±0.8а 8.2±0.8а 
Lacto-G 
_%_ 
E-RFC,% 
 
60.0±9.8 
54.1±1.0* 
 
44.0±9.9 
49.0±1.4 
 
40.0±9.8 
42.1±1.1 
NSC,% 5.0±0.7 2.7±0.5 2.3±0.6 
Narimax-plus 
% 
E-RFC,% 
 
44.0±9.9 
51.1±1.1 
 
40.0±9.8 
47.2±1.3 
 
32.0±9.3 
41.2±1.1 
NSC,% 4.8±0.7b 0.9±0.7b 1.4±0.7b 
Hypo ergic type reaction 
Bifilax-immuno 
_%_ 
E-RFC, % 
 
16.0±7.3 
44.2±0.7* 
 
 
 
 
49.1±1.4 
 
20.0±8.0 
39.0±1.2* 
 
 
 
 
46.3±1.2 
 
24.0±8.5 
33.2±1.2* 
 
 
 
 
39.8±1.1 
Lacto-G 
_%_ 
E-RFC, % 
 
16.0±7.3 
43.1±1.0 
 
24.0±8.5 
37.2±1.3* 
 
32.0±9.3 
30.3±1.1* 
Narimax-plus 
_%_ 
E-RFC, % 
 
28.0±8.9 
42.1±1.1 
 
24.0±8.5 
34.1±1.1* 
 
32.0±9.3 
28.3±1.1* 
Without alteration 
Bifilax-immuno 
_%_ 
 
16.0±7.3 
 
 
 
16.0±7.3 
 
 
 
20.0±8.0 
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E-RFC, % 48.5±1.4  
 
49.1±1.4 
45.8±1.3  
 
46.3±1.2 
38.6±1.3  
 
39.8±1.1 
Lacto-G 
_%_ 
E-RFC, % 
 
24.0±8.5 
48.8±1.1 
 
32,0±9,3 
46.2±1.1 
 
28.0±8.9 
38.7±1.1 
Narimax-plus 
_%_ 
E-RFC, % 
 
28.0±8.9 
48.5±1.4 
 
36.0±9.6 
46.9±1.1 
 
36.0±9.6 
39.1±1.1 
Note: * - reliability of the differences to the control values (р<0.05) 
а – reliability of the differences between Bifilax-immuno and Lacto-G (р<0.05); 
b-  reliability of differences between Bifilax-immuno and Narimax-plus (р<0.05); 
с-  reliability of differences between Lacto-G and Narimax-plus (р<0.05); 
 
In the total number of examined children, the prevalence of hyper ergic type reaction in 
loading test in vitro to Bifilax-immuno was equal to 62.7±5.6%, Lacto-G to 48.0±5.8%, 
Narimax-plus to 38.7±5.7% cases.  
Thus, we revealed interrelation between the expression of ID in children and the functional 
activity of T-lymphocytes in the blood plasma of patients with CHB with background giardiasis. 
Increase of ID was characterized by decrease of lymphocytes’ ability to form E-rosettes, 
indicating failure of receptor tendency in T-lymphocytes to the studied preparations. The most 
sensitive probiotic was Bifilax-immuno containingL.paracaseiCRL-431, B. animal is BB-12. In 
vitro conditions these strains with antimicrobial and immune modulating properties promoted 
production of T-lymphocytes, by these means having a complex impact on the intensification of 
receptor tendency for the formation of E-RFC. Apparently, that indicated deficiency of these 
strains in intestine of the examined children. Nevertheless, most of the performed clinical and 
experimental tests testify that probiotic strains of lacto bacteria L.paracaseiCRL-431, Ent. 
Faecium are perceived by T-lymphocytes and stimulate inflammatory response, intensifying 
production of Th1 and IL-1, INF-α. They stimulate phagocyte activity of neutrophils and 
secretion of SIgА, while bifido bacteria stimulate Th-reg and, correspondingly, secretion of 
TGF-β, IL-10, by these means promoting formation of immunological tolerance [17, 18]. That 
can explain the necessity of decoding of the qualitative composition of intestinal micro flora, 
especially L.paracasei, B.animal is BB-12 subclasses in children with CHB and giardiasis. 
The next stage in our study was assessment of the efficiency of biopreparations in the 
correction ofIDin children with CHB with background giardiasis.Prescription of individually 
chosen preparations had a significant effect on the dynamics of the basic clinical symptoms in 
children with CHB and background giardiasis. Particularly, clinically 78.4% of the children 
(versus 38.3% in the comparison group, р<0.05) had positive response. That was reflected in the 
improvement of children’s health, leveling of complaints about fatigue, loss of appetite, and 
stomachache among the children of the basic group (р<0.05-0.001). Reliably less often we 
registered symptoms such as diminishing of flatulence (19.5±6.4%), rumbling in stomach 
(16.2±6.1%), tongue plaque and stool disorders (13.3±6.2%, р<0.05). The sizes of liver and 
spleen diminished 2.0 and 1.8 folds respectively (р<0.05 to the comparison group).   
With the background complex therapy with individual approach to biocorrection of ID 
parameters of biochemical homeostasis improved by means of decrease of the expression of 
cytolysis syndromes (ALAT and ASAT 2.5 folds, р<0.01 to the control), cholestasis (total and 
direct bilirubin 2 folds), and mesenchymal-inflammatory (gamma-globulin and thymolturbidity 
test 1.8 folds, respectively, р<0.001). 
Comparativeanalysisofquantitativeandqualitativealterationsintheintestinalmicrofloraofthe
examinedchildren, independently of the activity of the disease, revealed that after the complex 
therapy with individually chosen probiotics the number of bifida and lactobacteria in normal 
limits was noted in 34.7 ± 5.5% and 30.7 ± 5.4%  of the patients respectively (versus 13.3 ± 
6.2% in the comparison group p < 0.01) (Table 2).The number  of significant decrease in 
Logarithm values of bifida and lacto bacteria (< 105 CFU/g) in the patients of the basic group at 
the end of the therapy course were identified 3.7 and 3.1 folds less often (p < 0.001 to the 
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control). Normal enzyme activity of colon bacilli was registered reliably more often among the 
patients of the basic group (p < 0.01) and hemolytic E. coli were isolated 2.9 folds less often (p > 
0.05 compared to the control). The normal number of enterococci (107—108 CFU/g) in the 
patients of the basic group was registered almost in half of the cases (50.7 ± 5.8% versus 16.7 ± 
6.8% in the comparison group, p<0.001). Increase of the number of enterococci above 108 
CFU/g in patients of the basic group after the therapy was not registered, while in the control 
group increase was observed in 13.3±6.2% of the cases (p<0.05). Decrease in the increased 
number of enterococci up to 107 CFU/g in the patients of the basic group after the therapy with 
probiotic was registered in 49.3 ± 5.7% of the cases (p < 0.02). Apparently, an individually 
chosen bio preparation in the conditions of impaired secretory, motor, and barrier function of 
intestine in children with CHB with giardiasis promotes adhesion of probiotic strains to intestinal 
epithelium. They attach to the epithelium by means of glycol conjugated receptors, providing 
colonization resistance and preventing pathogen adhesion and invasion. Finally, all these 
mechanisms contribute to the rise of epithelial resistance, intensifying its barrier function and 
protection [19].  
Table 2.  
Dynamic alterations in intestinal micro flora in children with CHB with background 
giardiasis (%). 
 
Ig (CFU/g) of intestinal micro flora 
 
Before the 
therapy 
n=105 
After the therapy  
Р Basic 
group 
n=150 
Comparison 
group 
n=60 
Bifida bacteria: 
- normal (109-1010) 
- moderate decrease (106-105) 
- significant decrease (<105) 
 
4.7±2.1 
20.9±4.0 
74.4±4.3 
 
34.7±5.5 
49.3±5.7 
16.0±4.3 
 
13.3±6.2 
23.3±7.7 
63.4±8.8 
 
<0.001 
<0.05 
<0.001 
Lactobacteria: 
- normal(107-108) 
- moderate decrease(106-105) 
- significant decrease (<105) 
4.7±2.1 
29.5±4.5 
65.8±4.6 
30.7±5.4 
50.7±5.8 
18.6±4.5 
 
13.3±6.2 
33.3±8.6 
53.4±9.1 
 
<0.01 
>0.05 
<0.001 
E.coliтипичные: 
- normal(107-108) 
- decrease (<107) 
- increase (>108) 
 
5.7±2.3 
74.3±4.3 
20.0±3.9 
 
34.7±5.5 
49.3±5.7 
16.0±4.3 
 
16.7±6.8 
70.0±8.4 
13.3±6.2 
 
<0.01 
<0.02 
>0.05 
E.colilactose negative 30.5±4.5 18.6±4.5 26.7±8.0 >0.05 
E.colihemolytic  20.0±3.9 5.3±2.6 16.7±6.8 >0.05 
Enterococci: 
- normal(107-108) 
- decrease (<107) 
- increase (>108) 
 
6.7±2.4 
74.3±4.3 
19.0±3.8 
 
50.7±5.8 
49.3±5.7 
- 
 
16.7±6.8 
70.0±8.4 
13.3±6.2 
 
<0.001 
<0.02 
<0.05 
Staphylacoccus aureus 29.5±4.5 9.3±3.4 20.0±7.3 <0.05 
Staphylococcus epidermidis 29.5±4.5 5.3±2.6 20.0±7.3 <0.05 
Proteus 14.3±3.4 - 10.0±5.5 <0.02 
Klebsiella 14.3±3.4 9.3±3.4 10.0±5.5 >0.05 
Candida 55.2±4.9 18.6±4.5 36.7±8.8 <0.02 
2-component RPM associations 20.0±3.9 9.3±3.4 16.7±6.8 >0.05 
3-component RPM associations 10.5±3.0 - 10.0±5.5 <0.02 
4-component RPM associations 5.7±2.3 - 3.3±3.3 >0.05 
Note: Р – statistically reliable differences of the values with background therapy. 
 
Among the representatives of relatively pathogenic micro flora (RPM) — St. aureus et St. 
epidermidis were revealed 2.3 and 3.5 folds less often (9.3 ± 3.4% and 5.3 ± 2.6% versus 20.0 ± 
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7.3% of the cases in comparison group, p < 0.05) among the children of the basic group after the 
therapy. After the therapy we could not detect non-fermenting Proteus among the children of the 
basic group, while in the control group the values almost did not change (p<0.05). In the basic 
group of patients, the number of yeast-like Candida fungi and revealed RPM associations 
diminished notably, while 3 and 4-component associations disappeared at all (p<0.05—0.001).  
Thus, performed correction of ID in children with CHB with background giardiasis, taking into 
account their individual sensitivity to a bio preparation, different from the control group, 
promoted significant improvement of micro ecological status in intestine due to more expressed 
normalizing impact on qualitative and quantitative composition of the micro flora. Application of 
anti-giardiasis therapy with individually chosen very sensitive bio preparation for the correction 
of intestinal dysbacteriosis in children with CHB provided achievement of stabilization (60.0%) 
and regression of the pathological process in liver, prevention of unfavorable outcomes such as 
liver cirrhosis and hepatocellular carcinoma [20]. 
CONCLUSION 
1. We revealed an interrelation between the functional activity of T-lymphocytes and 
expression of ID in children with CHB and concomitant giardiasis. Decrease of the number 
of E-RFC directly proportional to the expression of ID was determined, which indicated 
the failure of receptor tendency in T-lymphocytes and sensitivity to bio preparations.  
2. In children with CHB and giardiasis the most sensitive bio preparation in vitro test was 
Bifilax-immuno (62.7%) in comparison with Lacto-G (48.0%), and Narimax-plus (38.7%, 
p < 0.05).  
3. Differentiated approach to the choice of probiotic for ID correction provided the rise of 
therapy efficiency in children with CHB with concomitant giardiasis by 40.1%. 
development of clinical, biochemical, and microbiological remission was achieved using 
Bifilax-immuno in 76.5%,  Lacto-G in 64.4%, and Narimax-plus in 62.0% of the cases 
respectively (p < 0.01).  
4. Children with CHB with concomitant giardiasis should have loading test in vitro together 
with ID test for the prescription of effective and targeted correction taking into account 
individual sensitivity of an organism to biopreparations. 
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